Novel aminotetrazole derivatives as selective STAT3 non-peptide inhibitors

European Journal of Medicinal Chemistry

Volumn 103, Issue , 2015, Pages 163-174

  Pallandre, Jean René ^a   Borg, Christophe ^a   Rognan, Didier ^b   Boibessot, Thibault ^a   Luzet, Vincent ^a   Yesylevskyy, Semen ^a,c   Ramseyer, Christophe ^a   Pudlo, Marc ^a  

^a UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c INSTITUTE OF PHYSICS   (Ukraine)

Author keywords

Aminotetrazole; Anticancer drug; Inflammation; Small molecule inhibitor; STAT3

Indexed keywords

AMINOTETRAZOLE DERIVATIVE; PROTEIN INHIBITOR; STAT1 PROTEIN; STAT3 PROTEIN; TETRAZOLE DERIVATIVE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; STAT3 PROTEIN, HUMAN; STAT3 PROTEIN, MOUSE;

ARTICLE; CELL GROWTH; CELL SURVIVAL; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; TH17 CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; MOUSE; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MICE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAZOLES;

EID: 84941285460     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2015.08.054     Document Type: Article

References (62)

1. J.E. Darnell Transcription factors as targets for cancer therapy Nat. Rev. Cancer 2 2002 740 749 10.1038/nrc906
2. J.E. Darnell STATs and gene regulation Science 277 1997 1630 1635 10.1126/science.277.5332.1630
3. A.C. Greenlund, M.A. Farrar, B.L. Viviano, and R.D. Schreiber Ligand-induced IFN gamma receptor tyrosine phosphorylation couples the receptor to its signal transduction system (p91) EMBO J. 13 7 1994 1591 1600
4. K. Shuai, G.R. Stark, I.M. Kerr, and J.E. Darnell Jr. A single phosphotyrosine residue of Stat91 required for gene activation by interferon-gamma Science 261 1993 1744 1746 10.1126/science.7690989
5. J.N. Ihle STATs: signal transducers and activators of transcription Cell 84 1996 331 334
6. M.H. Heim The Jak-Stat pathway: cytokine signaling from the receptor to the nucleus J. Recept. Signal. Transduct. Res. 19 1999 75 120 10.3109/10799899909036638
7. H. Yu, and R. Jove The STATs of cancer - new molecular targets come of age Nat. Rev. Cancer 4 2004 97 105 10.1038/nrc1275
8. S. Pensa, G. Regis, D. Boselli, F. Novelli, and V. Poli STAT1 and STAT3 in tumorigenesis: two sides of the same coin? A. Stephanou, JAK-STAT Pathway in Disease 2008 Landes Bioscience Austin 100 121
9. A. Amadi-Obi, C.R. Yu, X. Liu, R.M. Mahdi, G.L. Clarke, R.B. Nussenblatt, I. Gery, Y.S. Lee, and C.E. Egwuagu TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1 Nat. Med. 13 6 2007 711 718 10.1038/nm1585
10. L. Costantino, and D. Barlocco STAT3 as a target for cancer drug discovery Curr. Med. Chem. 15 2008 834 843 10.2174/092986708783955464
11. A.K. Mankan, and F.R. Greten Inhibiting signal transducer and activator of transcription 3: rationality and rationale design of inhibitors Expert Opin. Invest. Drugs 20 2011 1263 1275 10.1517/13543784.2011.601739
12. A. Lavecchia, C. Di Giovanni, and E. Novellino STAT-3 Inhibitors: state of the art and new horizons for cancer treatment Curr. Med. Chem. 18 2011 2359 2375 10.2174/092986711795843218
13. B.D. Page, D.P. Ball, and P.T. Gunning Signal transducer and activator of transcription 3 inhibitors: a patent review Expert Opin. Ther. Pat. 21 1 2011 65 83 10.1517/13543776.2011.539205
14. B. Debnath, S. Xu, and N. Neamati Small molecule inhibitors of signal transducer and activator of transcription 3 (Stat3) protein J. Med. Chem. 55 15 2012 6645 6668 10.1021/jm300207s
15. http://bioinfo-pharma.u-strasbg.fr/bioinfo.
16. S. Becker, B. Groner, and C.W. Muller Three-dimensional structure of the Stat3beta homodimer bound to DNA Nature 394 1998 145 151 10.1038/28101
17. G. Marcou, and D. Rognan Optimizing fragment and scaffold docking by use of molmecular interaction fingeprints J. Chem. Inf. Model 47 2007 195 207 10.1021/ci600342e
18. R. Buettner, R. Corzano, R. Rashid, J. Lin, M. Senthil, M. Hedvat, A. Schroeder, A. Mao, A. Herrmann, J. Yim, H. Li, Y.C. Yuan, K. Yakushijin, F. Yakushijin, N. Vaidehi, R. Moore, G. Gugiu, T.D. Lee, R. Yip, Y. Chen, R. Jove, D. Horne, and J.C. Williams Alkylation of cysteine 468 in Stat3 defines a novel site for therapeutic development ACS Chem. Biol. 6 5 2011 432 443 10.1021/cb100253e
19. L. Klampfer, J. Huang, L.A. Swaby, and L. Augenlicht Requirement of histone deacetylase activity for signaling by STAT1 J. Biol. Chem. 279 29 2004 30358 30368 10.1074/jbc.M401359200
20. H. Song, R. Wang, S. Wang, and J. Lin A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells Proc. Natl. Acad. Sci. U. S. A. 102 13 2005 4700 4705 10.1073/pnas.0409894102
21. G. Niu, K.L. Wright, M. Huang, L. Song, E. Haura, J. Turkson, S. Zhang, T. Wang, D. Sinibaldi, D. Coppola, R. Heller, L.M. Ellis, J. Karras, J. Bromberg, D. Pardoll, R. Jove, and H. Yu Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis Oncogene 21 13 2002 2000 2008 10.1038/sj/onc/1205260
22. R. Bedel, A. Thiery-Vuillemin, C. Grandclement, J. Balland, J.P. Remy-Martin, B. Kantelip, J.R. Pallandre, X. Pivot, C. Ferrand, P. Tiberghien, and C. Borg Novel role for STAT3 in transcriptional regulation of NK immune cell targeting receptor MICA on cancer cells Cancer Res. 71 5 2011 1615 1626 10.1158/0008-5472
23. C.E. Egwuagu STAT3 in CD4+ T helper cell differentiation and inflammatory diseases Cytokine 47 3 2009 149 156 10.1016/j.cyto.2009.07.003
24. D. Bhasin, K. Cisek, T. Pandharkar, N. Regan, C. Li, B. Pandit, J. Lin, and P.-K. Li Design, synthesis, and studies of small molecule STAT3 inhibitors Bioorg. Med. Chem. Lett. 18 2008 391 395 10.1016/j.bmcl.2007.10.031
25. X. Ren, L. Duan, Q. He, Z. Zhang, Y. Zhou, D. Wu, J. Pan, D. Pei, and K. Ding Identification of niclosamide as a new small-molecule inhibitor of the STAT3 signaling pathway ACS Med. Chem. Lett. 1 2010 454 459 10.1021/ml100146z
26. H. Chen, Z. Yang, C. Ding, L. Chu, Y. Zhang, K. Terry, H. Liu, Q. Shen, and J. Zhou Fragment-based drug design and identification of HJC0123, a novel orally bioavailable STAT3 inhibitor for cancer therapy Eur. J. Med. Chem. 62 2013 498 507 10.1016/j.ejmech.2013.01.023
27. J. Schust, B. Sperl, A. Hollis, T.U. Mayer, and T. Berg Stattic: a small-molecule inhibitor of STAT3 activation and dimerization Chem. Biol. 13 2006 1235 1242 10.1016/j.chembiol.2006.09.018
28. H. Li, A. Liu, Z. Zhao, Y. Xu, J. Lin, D. Jou, and C. Li Fragment-based drug design and drug repositioning using multiple ligand simultaneous docking (MLSD): identifying celecoxib and template compounds as novel inhibitors of signal transducer and activator of transcription 3 (STAT3) J. Med. Chem. 54 2011 5592 5596 10.1021/jm101330h
29. V.M. Shahani, P. Yue, S. Haftchenary, W. Zhao, J.L. Lukkarila, X. Zhang, D. Ball, C. Nona, P.T. Gunning, and J. Turkson Identification of purine-scaffold small-molecule inhibitors of Stat3 activation by QSAR Studies ACS Med. Chem. Lett. 2 2011 79 84 10.1021/ml100224d
30. K. Matsuno, Y. Masuda, Y. Uehara, H. Sato, A. Muroya, O. Takahashi, T. Yokotagawa, T. Furuya, T. Okawara, M. Otsuka, N. Ogo, T. Ashizawa, C. Oshita, S. Tai, H. Ishii, Y. Akiyama, and A. Asai Identification of a new series of STAT3 inhibitors by virtual screening ACS Med. Chem. Lett. 1 2010 371 375 10.1021/ml1000273
31. C. Saturnino, C. Palladino, M. Napoli, M.S. Sinicropi, A. Botta, M. Sala, A. Carcereri de Prati, E. Novellino, and H. Suzuki Synthesis and biological evaluation of new N-alkylcarbazole derivatives as STAT3 inhibitors: preliminary study Eur. J. Med. Chem. 60 2013 112 119 10.1016/j.ejmech.2012.11.004
32. W. Yu, H. Xiao, J. Lin, and C. Li Discovery of novel STAT3 small molecule inhibitors via in silico site-directed fragment-based drug design J. Med. Chem. 56 2013 4402 4412 10.1021/jm400080c
33. J. Xu, D.C. Cole, C.-P.B. Chang, R. Ayyad, M. Asselin, W. Hao, J. Gibbons, S.A. Jelinsky, K.A. Saraf, and K. Park Inhibition of the signal transducer and activator of transcription-3 (STAT3) signaling pathway by 4-oxo-1-phenyl-1,4-dihydroquinoline-3-carboxylic acid esters J. Med. Chem. 51 2008 4115 4121 10.1021/jm701271y
34. M. Zhang, W. Zhu, and Y. Li Discovery of novel inhibitors of signal transducer and activator of transcription 3 (STAT3) signaling pathway by virtual screening Eur. J. Med. Chem. 62 2013 301 310 10.1016/j.ejmech.2013.01.009
35. M. Zhang, W. Zhu, N. Ding, W. Zhang, and Y. Li Identification and characterization of small molecule inhibitors of signal transducer and activator of transcription 3 (STAT3) signaling pathway by virtual screening Bioorg. Med. Chem. Lett. 23 2013 2225 2229 10.1016/j.bmcl.2013.01.056
36. K. Siddiquee, S. Zhang, W.C. Guida, M.A. Blaskovich, B. Greedy, H.R. Lawrence, M.L.R. Yip, R. Jove, M.M. McLaughlin, N.J. Lawrence, S.M. Sebti, and J. Turkson Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity Proc. Natl. Acad. Sci. U. S. A. 104 18 2007 7391 7396 10.1073/pnas.0609757104
37. S. Fletcher, B.D.G. Page, X. Zhang, P. Yue, Z.H. Li, S. Sharmeen, J. Singh, W. Zhao, A.D. Schimmer, S. Trudel, J. Turkson, and P.T. Gunning Antagonism of the Stat3-Stat3 protein dimer with salicylic acid based small molecules ChemMedChem 6 2011 1459 1470 10.1002/cmdc.201100194
38. B.D.G. Page, S. Fletcher, P. Yue, Z. Li, X. Zhang, S. Sharmeen, A. Datti, J.L. Wrana, S. Trudel, A.D. Schimmer, J. Turkson, and P.T. Gunning Identification of a non-phosphorylated, cell permeable, small molecule ligand for the Stat3 SH2 domain Bioorg. Med. Chem. Lett. 21 2011 5605 5609 10.1016/j.bmcl.2011.06.056
39. X. Zhang, P. Yue, S. Fletcher, W. Zhao, P.T. Gunning, and J. Turkson A novel small-molecule disrupts Stat3 SH2 domainphosphotyrosine interactions and Stat3-dependent tumor processes Biochem. Pharmacol. 79 2010 1398 1409 10.1016/j.bcp.2010.01.001
40. S. Fletcher, J. Singh, X. Zhang, P. Yue, B.D.G. Page, S. Sharmeen, V.M. Shahani, W. Zhao, A.D. Schimmer, J. Turkson, and P.T. Gunning Disruption of transcriptionally active stat3 dimers with non-phosphorylated, salicylic acid-based small molecules: potent in vitro and tumor cell activities ChemBioChem 10 2009 1959 1964 10.1002/cbic.200900172
41. W. Hao, Y. Hu, C. Niu, X. Huang, C.-P.B. Chang, J. Gibbons, and J. Xu Discovery of the catechol structural moiety as a Stat3 SH2 domain inhibitor by virtual screening Bioorg. Med. Chem. Lett. 18 2008 4988 4992 10.1016/j.bmcl.2008.08.032
42. X. Zhang, P. Yue, B.D.G. Page, T. Li, W. Zhao, A.T. Namanja, D. Paladino, J. Zhao, Y. Chen, P.T. Gunning, and J. Turkson Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts Proc. Natl. Acad. Sci. U. S. A. 109 24 2012 9623 9628 10.1073/pnas.1121606109
43. B.D.G. Page, D.C. Croucher, Z.H. Li, S. Haftchenary, V.H. Jimenez-Zepeda, J. Atkinson, P.A. Spagnuolo, Y.L. Wong, R. Colaguori, A.M. Lewis, A.D. Schimmer, S. Trudel, and P.T. Gunning Inhibiting aberrant signal transducer and activator of transcription protein activation with tetrapodal, small molecule Src homology 2 domain binders: promising agents against multiple myeloma J. Med. Chem. 56 2013 7190 7200 10.1021/jm3017255
44. P.T. Gunning, M.P. Glenn, K.A. Siddiquee, W.P. Katt, E. Masson, S.M. Sebti, J. Turkson, and A.D. Hamilton Targeting protein-protein interactions: suppression of Stat3 dimerization with rationally designed small-molecule, nonpeptidic SH2 domain binders ChemBioChem 9 2008 2800 2803 10.1002/cbic.200800291
45. K.A.Z. Siddiquee, P.T. Gunning, M. Glen, W.P. Katt, S. Zhang, C. Schroeck, S.M. Sebti, R. Jove, A.D. Hamilton, and J. Turkson An oxazole-based small-molecule Stat3 inhibitor modulates Stat3 stability and processing and induces antitumor cell effects ACS Chem. Biol. 2 2007 787 798 10.1021/cb7001973
46. P.K. Mandai, W.S. Lião, and J.S. McMurray Synthesis of phosphatase-stable, cell-permeable peptidomimetic prodrugs that target the SH2 domain of Stat3 Org. Lett. 11 2009 3394 3397 10.1021/ol9012662
47. D.R.I.V. Coleman, Z. Ren, P.K. Mandal, A.G. Cameron, G.A. Dyer, S. Muranjan, M. Campbell, X. Chen, and J.S. McMurray Investigation of the binding determinants of phosphopeptides targeted to the Src homology 2 domain of the signal transducer and activator of transcription 3. Development of a high-affinity peptide inhibitor J. Med. Chem. 48 2005 6661 6670 10.1021/jm050513m
48. V.M. Shahani, P. Yue, S. Fletcher, S. Sharmeen, M.A. Sukhai, D.P. Luu, X. Zhang, H. Sun, W. Zhao, A.D. Schimmer, J. Turkson, and P.T. Gunning Design, synthesis, and in vitro characterization of novel hybrid peptidomimetic inhibitors of STAT3 protein Bioorg. Med. Chem. 19 2011 1823 1838 10.1016/j.bmc.2010.12.010
49. P.T. Gunning, W.P. Katt, M. Glenn, K. Siddique, J.S. Kim, R. Jove, S.M. Sebti, J. Turkson, and A.D. Hamilton Isoform selective inhibition of STAT1 or STAT3 homo-dimerization via peptidomimetic probes: structural recognition of STAT SH2 domains Bioorg. Med. Chem. Lett. 17 2007 1875 1878 10.1016/j.bmcl.2007.01.077
50. K. Shuai, C. Schindler, V.R. Prezioso, and J.E. Darnell Jr. Activation of transcription by IFN-gamma:tyrosine phosphorylation of a91-kD DNA binding protein Science 258 1992 1808 1812 10.1126/science.1281555
51. C. Schindler, K. Shuai, V.R. Prezioso, and J.E. Darnell Jr. Interferon-dependenttyrosine phosphorylationofalatentcytoplasmictranscriptionfactor Science 257 1992 809 813 10.1126/science.1496401
52. J.F. Bromberg, C.M. Horvath, Z. Wen, R.D. Schreiber, and J.E. Darnell Jr. Transcriptionally active Stat1 is required for the antiproliferative effects of both inter- feron alpha and interferon gamma Proc. Natl. Acad. Sci. U. S. A. 93 1996 7673 7678
53. G.P. Dunn, C.M. Koebel, and R.D. Schreiber Interferons, immunity and cancer immunoediting Nat. Rev. Immunol. 6 2006 836 848 10.1038/nri1961
54. S. Huang, C.D. Bucana, M. Van Arsdall, and I.J. Fidler STAT1 negatively regulates angiogenesis, tumorigenicity and metastasis of tumor cells Oncogene 21 2002 2504 2512 10.1038/sj/onc/1205341
55. Pipeline Pilot, version 7.5, Accelrys, San Diego, CA 92121, USA.
56. Filter, version 2., OpenEye Scientific Software, Santa Fe, NM 87508, USA.
57. Chemaxon Kft, 1031 Budapest, Hungary.
58. SYBYL, version 8.0, Tripos, St.Louis, MO 63101, USA.
59. O. Korb, T. Stützle, and T.E. Exner Empirical scoring functions for advanced protein-ligand docking with PLANTS J. Chem. Inf. Model. 49 2009 84 96 10.1021/ci800298z
60. M. Biasini, S. Bienert, A. Waterhouse, K. Arnold, G. Studer, T. Schmidt, F. Kiefer, T.G. Cassarino, M. Bertoni, L. Bordoli, and T. Schwede SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information Nucleic Acids Res. 42 2014 252 258 10.1093/nar/gku340 (Online)
61. O. Trott, and A.J. Olson AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading J. Comput. Chem. 31 2010 455 461 10.1002/jcc.21334
62. S.O. Yesylevskyy Pteros: fast and easy to use open-source C++ library for molecular analysis J. Comput. Chem. 33 2012 1632 1636 10.1002/jcc.22989